Biotech Firm Lycia Raises $317.5 Million in US IPO
The allergy and autoimmune disease company priced its initial public offering at the top of its range.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
2 publishers have covered this in 3 articles since 23 Oct 2026. Bloomberg.com published first, on 23 October at 00:50 UTC; Quartz followed 16h 07m later. The most recent article, from Quartz, appeared on 23 October at 17:00 UTC.
Outlets reporting it: Bloomberg.com (major outlet), Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Lycia Therapeutics Inc.